Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)

 Full screen view
Filter results: >>>>
Cell Small Molecule Primary Target Pathway GR50 GRmax GR_AOC Death_AUC GR Hill Coefficient GEC50 GR r2
SUM159PT Ipatasertib
AKT
PI3K/mTOR
9.2403
 0.4884 0.1149 0.0020 0.9180
2.8242
0.99791
SUM159PT Alpelisib
PI3Ka
PI3K/mTOR
4.3125
 0.2818 0.1409 0.0003 0.7761
8.5413
0.99788
SUM159PT Taselisib
PI3Ka, g, d
PI3K/mTOR
0.024971
 0.0916 0.5859 0.0023 1.1458
0.019444
0.99527
SUM159PT TGX221
PI3Kb
PI3K/mTOR
Inf
 0.9906 -0.0088 -0.0001 0.0000
Inf
-0.54094
SUM159PT Torin2
mTOR/ATM/ATR
PI3K/mTOR
0.014492
 0.1057 0.4137 0.0050 1.4641
0.011782
0.9977
SUM159PT Everolimus
mTOR1
PI3K/mTOR
Inf
 0.6876 0.3173 -0.0017 0.0000
Inf
0.45421
SUM159PT INK-128
mTORC1/2
PI3K/mTOR
0.018735
 0.1504 0.4832 0.0004 1.5649
0.014424
0.99839
SUM159PT PF-4708671
p70S6K
PI3K/mTOR
22.2837
 0.7309 0.0337 0.0128 0.9688
68.5361
0.98758
SUM159PT Buparlisib
pan PI3K
PI3K/mTOR
1.5871
 -0.1942 0.2253 0.0613 1.5281
2.1811
0.99923
SUM159PT Pictilisib
pan PI3K
PI3K/mTOR
1.2625
 0.0942 0.2390 -0.0024 0.9852
1.2984
0.99746
SUM159PT Ceritinib
ALK
RTK
1.5606
 -0.3800 0.2590 0.1427 2.5153
1.9758
0.99862
SUM159PT Neratinib
EGFR/HER2
RTK
1.0155
 0.3337 0.1585 0.0028 0.9807
0.58582
0.99938
SUM159PT Tivantinib
MET
RTK
0.37997
 -0.1921 0.3954 0.1806 2.0717
0.4458
0.9982
SUM159PT Cediranib
VEGFR/cKIT
RTK
8.1187
 0.3173 0.0491 0.0085 2.1882
12.8042
0.99762
SUM159PT Cabozantinib
VEGFR2/MET
RTK
5.7873
 0.1744 0.0876 0.0357 1.3651
12.895
0.99886